

CITATION REPORT

List of articles citing

Outcome and prognostic markers in severe drug-induced liver disease

DOI: 10.1002/hep.20800
Hepatology, 2005, 42, 481-9.

Source: <https://exaly.com/paper-pdf/38329938/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
483	Multivariate probability-based detection of drug-induced hepatic signals. 2006 , 25, 37-54		19
482	Chapter 5 Idiosyncratic Drug Reactions: Clinical Evidence for Mechanistic Hypotheses. 2006 , 1, 139-183		
481	Drug-related hepatotoxicity. 2006 , 354, 731-9		736
480	Drug hepatotoxicity. 2006 , 10, 207-17, vii		48
479	Clinical characteristics and prognostic markers in disulfiram-induced liver injury. 2006 , 44, 791-7		60
478	Dissimilarity Measures for Detecting Hepatotoxicity in Clinical Trial Data. 2006 ,		1
477	Current World Literature. 2006 , 11, 311-350		
476	Drug-induced liver disease. 2006 , 22, 223-33		21
475	How can <i>Qiy@ law</i> help the clinician?. 2006 , 15, 235-9		34
474	Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. 2006 , 24, 1187-95		149
473	Drug-induced liver injury: Hy@ rule revisited. 2006 , 79, 521-8		81
472	Halothane induces oxidative stress and NF-kappaB activation in rat liver: protective effect of propofol. 2006 , 227, 53-61		38
471	An assessment of statin safety by hepatologists. 2006 , 97, 77C-81C		263
470	Drug-induced liver injury: summary of a single topic clinical research conference. <i>Hepatology</i> , 2006 , 43, 618-31	11.2	227
469	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006 , 44, 1581-8	11.2	223
468	Needles in haystacks. 2007 , 102, 2444-6		2
467	Gather and weigh the evidence when judging whether a drug has induced liver injury. 2007 , 23, 23-26		1

466	[Toxic liver disease due to drugs, herbs and dietary supplements: diagnostic approaches]. 2007 , 45, 195-208	5
465	Drug-Induced Liver Disease. 2007 , 1-11	2
464	A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation. 2007 , 39, 3287-91	11
463	Slimming at all costs: Herbalife-induced liver injury. 2007 , 47, 444-6	17
462	Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. 2007 , 11, 563-75, vi-vii	117
461	A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. 2007 , 1, 88	16
460	Liver Immunology. 2007 ,	4
459	Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. 2007 , 102, 558-62; quiz 693	89
458	Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. 2007 , 4, 895-910	21
457	Hepatotoxicity due to antibiotics. 2007 , 11, 549-61, vi	41
456	Statins and monitoring of liver function tests. <i>Drug Safety</i> , 2007 , 30, 1-4	5.1 2
455	Drug-induced liver injury. <i>Drug Safety</i> , 2007 , 30, 277-94	5.1 215
454	Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. <i>Drug Safety</i> , 2007 , 30, 805-15	5.1 38
453	Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. 2007 , 132, 272-81	277
452	Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. 2007 , 11, 477-505, v	101
451	Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. <i>World Journal of Gastroenterology</i> , 2007 , 13, 329-40	5.6 104
450	Drug induced liver injury. 247-270	
449	Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. 2007 , 19, 30-8	89

448	The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. 2007 , 25, 1411-21		115
447	Long-term follow-up of patients with mild to moderate drug-induced liver injury. 2007 , 26, 79-85		48
446	Monitoring liver safety in drug development: the GSK experience. 2007 , 49, 90-100		18
445	Idiosyncratic drug-induced liver injury: an overview. 2007 , 6, 673-84		137
444	The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. 2008 , 53, 1375-82		55
443	[Cholestasis and liver dysfunction in critical care patients]. 2008 , 57, 1172-82		0
442	Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease. 2008 , 43, 866-74		10
441	Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. <i>Hepatology</i> , 2008 , 47, 2003-9	11.2	294
440	What is idiosyncratic hepatotoxicity? What is it not?. <i>Hepatology</i> , 2008 , 47, 1813-5	11.2	37
439	Using controlled clinical trials to learn more about acute drug-induced liver injury. <i>Hepatology</i> , 2008 , 48, 1680-9	11.2	84
438	Hepatotoxicity associated with antiepileptic drugs. 2008 , 118, 281-90		108
437	Assessment of drug-induced liver injury in clinical practice. 2008 , 22, 141-58		54
436	Causality assessment in hepatotoxicity by drugs and dietary supplements. 2008 , 66, 758-66		80
435	COX-2 selective inhibitors in the treatment of osteoarthritis. 2008 , 38, 165-87		79
434	Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. <i>Drug Safety</i> , 2008 , 31, 325-34	5.1	22
433	Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. 2008 , 135, 1924-34, 1934.e1-4		620
432	Acute liver failure including acetaminophen overdose. 2008 , 92, 761-94, viii		147
431	A problem-oriented approach to liver disease in oncology patients. 2008 , 57, 987-1003		33

430	Idiosyncratic drug hepatotoxicity: a 2008 update. 2008 , 1, 261-76		14
429	Hepatotoxicity observed in clinical trials of amlaviroc (GW873140). 2008 , 52, 858-65		122
428	Acute liver failure due to drugs. 2008 , 28, 175-87		51
427	Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. 2008 , 20, 1182-93		104
426	Pregabalin as a probable cause of acute liver injury. 2008 , 20, 1049		23
425	Drug-Induced Liver Disease (DILI). 174-194		
424	Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. <i>Annals of Hepatology</i> , 2009 , 8, 184-195	3.1	17
423	Severe hepatotoxicity by Indian Ayurvedic herbal products: A structured causality assessment. <i>Annals of Hepatology</i> , 2009 , 8, 258-266	3.1	66
422	Rechallenge in drug-induced liver injury: the attractive hazard. 2009 , 8, 709-14		38
421	Biomarkers for the diagnosis and management of drug-induced liver injury. 2009 , 29, 393-9		56
420	Drug-induced liver injury following positive drug rechallenge. 2009 , 54, 84-90		45
419	Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. <i>Hepatology</i> , 2009 , 49, 250-7	11.2	89
418	Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. <i>Hepatology</i> , 2009 , 49, 2001-9	11.2	221
417	Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. 2009 , 15, 719-29		82
416	Liver disorders in the elderly. 2009 , 23, 909-17		10
415	Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?. 2009 , 85, 331-4		74
414	Drug-induced liver disease: an 8-year study of patients from one gastroenterological department. 2009 , 10, 195-200		12
413	Suspected black cohosh hepatotoxicity--challenges and pitfalls of causality assessment. 2009 , 63, 302-14		51

412	Reply to: Suspected black cohosh hepatotoxicity-Causality assessment versus safety signal. Quality versus quantity. 2009 , 64, 141-142		10
411	The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. 2009 , 50, 511-7		107
410	Immune-mediated adverse drug reactions. 2009 , 22, 24-34		83
409	Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. <i>Drug Safety</i> , 2009 , 32, 55-68	5.1	308
408	Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. <i>Drug Safety</i> , 2009 , 32, 359-78	5.1	87
407	Diagnosis, management and prevention of drug-induced liver injury. 2009 , 58, 1555-64		122
406	Drug-induced liver injury: what was new in 2008?. 2009 , 5, 843-60		46
405	Evidence-Based Liver Chemistry Monitoring in Drug Development. 2009 , 23, 149-158		3
404	Pharmacogenomics in drug induced liver injury. 2009 , 10, 956-70		61
403	Biomarkers for drug-induced liver injury. 2010 , 7, 367-375		6
402	Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. 2010 , 17, 426-40		62
401	Drug-induced acute liver failure and gastrointestinal complications. 2010 , 38, S175-87		17
400	Drug-induced liver injury: a clinical update. 2010 , 26, 222-6		95
399	Drug-Induced Liver Injury. 2010 , 235-242		
398	Hepatotoxicity of antibacterials: Pathomechanisms and clinical. 2010 , 38, 3-11		40
397	Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. <i>Hepatology</i> , 2010 , 52, 1143-55	11.2	120
396	Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <i>Hepatology</i> , 2010 , 52, 2065-76	11.2	479
395	Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. <i>Hepatology</i> , 2010 , 52, 2216-22	11.2	25

394	The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents. 2010 , 31, 1200-7		15
393	Review article: drug-induced liver injury in clinical practice. 2010 , 32, 3-13		94
392	Drug-induced liver injury. 2010 , 3-27		33
391	Relationship preserving feature selection for unlabelled clinical trials time-series. 2010 ,		0
390	Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. 2010 , 5, 212-22		21
389	Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. 2010 , 42, 143-8		23
388	Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. <i>Drug Safety</i> , 2010 , 33, 503-22	5.1	110
387	SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. 2010 , 138, 1357-64, 1364.e1-2		287
386	Risk factors for idiosyncratic drug-induced liver injury. 2010 , 138, 2246-59		233
385	Clinical Considerations of Drug-Induced Hepatotoxicity. 2010 , 369-381		2
384	Acute liver failure. 2010 , 376, 190-201		708
383	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. 2010 , 375, 998-1006		684
382	Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. 2010 , 105, 2396-404		147
381	Predicting and preventing acute drug-induced liver injury: what's new in 2010?. 2010 , 6, 1047-61		19
380	Hepatic safety of antibiotics used in primary care. 2011 , 66, 1431-46		118
379	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. 2011 , 7, 817-28		38
378	Hepatotoxicity related to antirheumatic drugs. 2011 , 7, 139-50		106
377	Liver Injury Due to Drugs and Herbal Agents. 2011 , 311-352		

376	Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. 2011 , 84, 54-9	60
375	[Hepatotoxicity, a global problem with local features: toward the creation of a Pan-American Hepatotoxicity Network]. 2011 , 34, 361-8	9
374	Causality assessment methods in drug induced liver injury: strengths and weaknesses. 2011 , 55, 683-691	130
373	IL-4 mediates dicloxacillin-induced liver injury in mice. 2011 , 200, 139-45	32
372	Estradiol and progesterone modulate halothane-induced liver injury in mice. 2011 , 204, 17-24	23
371	Drugs and Toxins Effects on the Liver. 2011 ,	1
370	Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. 2011 , 53, 182-9	59
369	Drug-induced cholestasis. <i>Hepatology</i> , 2011 , 53, 1377-87	11.2 236
368	Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. <i>Hepatology</i> , 2011 , 54, 1344-50	11.2 54
367	Clinical Features of Liver Disease. 2011 , 63-72	
366	Adverse Drug Reactions and Drug-drug Interactions. 2011 , 1569-1589	1
365	Drug-Induced Liver Injury. 2011 , 478-506	
364	Old and new antirheumatic drugs and the risk of hepatotoxicity. 2012 , 34, 622-8	25
363	Lapatinib-induced liver injury characterized by class II HLA and Gilbert® syndrome genotypes. 2012 , 91, 647-52	40
362	A developmental approach to drug-induced liver injury in newborns and children. 2012 , 19, 4581-94	12
361	A prospective nationwide study of drug-induced liver injury in Korea. 2012 , 107, 1380-7	139
360	Value of preapproval safety data in predicting postapproval hepatic safety and assessing the legitimacy of class warning. 2012 , 3, 13-24	3
359	Mechanism of exacerbative effect of progesterone on drug-induced liver injury. 2012 , 126, 16-27	20

358	Factores de riesgo y mecanismos de toxicidad hepática. Daño hepático inducido por medicamentos y tóxicos (excluido el alcohol). 2012 , 11, 573-580		
357	Drug-induced liver disease. 2012 , 16, 231-45		43
356	Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. 2012 , 130, 4-16		46
355	Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations. <i>Drug Safety</i> , 2012 , 35, 865-75	5.1	11
354	Suspected Herbal Hepatotoxicity. <i>Drug Safety</i> , 2012 , 35, 1091-1097	5.1	28
353	Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. 2012 , 56, 374-80		214
352	Latest advances in predicting DILI in human subjects: focus on biomarkers. 2012 , 8, 1521-30		21
351	An Update on Drug-induced Liver Injury. <i>Journal of Clinical and Experimental Hepatology</i> , 2012 , 2, 247-59	4.1	79
350	Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. 2012 , 64, 77-83		29
349	Akutes Leberversagen. 2012 , 7, 59-76		
348	Hepatic injury due to drugs, herbal compounds, chemicals and toxins. 2012 , 645-760		12
347	Greater Celandine hepatotoxicity: a clinical review. <i>Annals of Hepatology</i> , 2012 , 11, 838-848	3.1	34
346	Drug-induced liver injury: present and future. 2012 , 18, 249-57		92
345	Jaundice due to suspected statin hepatotoxicity: a case series. 2012 , 57, 1959-64		16
344	Clinical perspective: statins and the liver--harmful or helpful?. 2012 , 57, 1754-63		17
343	Which psychotropic medications induce hepatotoxicity?. 2012 , 34, 53-61		14
342	A pre-marketing ALT signal predicts post-marketing liver safety. 2012 , 63, 433-9		8
341	Drug-induced liver injury in the elderly. 2013 , 15, 299		27

340	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. 2013 , 87, 1315-530	837
339	An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. 2013 , 102, 3037-57	80
338	Hepatotoxicity of antibiotics: a review and update for the clinician. 2013 , 17, 609-42, ix	31
337	Clinical manifestations and treatment of drug-induced hepatotoxicity. 2013 , 17, 565-73, viii	11
336	Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. 2013 , 17, 643-56, ix	35
335	Acute liver failure. 2013 , 369, 2525-34	674
334	Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist. 2013 , 27, 165-191	14
333	Intrahepatic cholestasis in common chronic liver diseases. 2013 , 43, 1069-83	38
332	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. 2013 , 14, 63-73	17
331	How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. 2013 , 17, 749-67, xi	17
330	Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. 2013 , 144, 1419-25, 1425.e1-3; quiz e19-20	504
329	Drug-induced cholestasis. 2013 , 17, 191-209	49
328	Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. 2013 , 14, 541-54	33
327	Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. <i>Drug Safety</i> , 2013 , 36, 491-503	5.1 157
326	Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBase. 2013 , 53, 435-43	11
325	Drug-Induced Liver Injury: Introduction and Overview. 2013 , 3-14	25
324	Clinical Manifestations and Management of Drug-Induced Liver Diseases. 2013 , 229-240	0
323	Biomarkers for Drug-Induced Liver Injury. 2013 , 275-286	3

322	Causality Assessment. 2013 , 287-302		1
321	Nonsteroidal Antiinflammatory Drugs and Leukotriene Receptor Antagonists. 2013 , 369-401		6
320	Hepatotoxicity of Antimicrobials and Antifungal Agents. 2013 , 463-481		6
319	Chronic Liver Disease from Drugs. 2013 , 677-685		
318	Regulatory Perspectives. 2013 , 689-712		1
317	Antibiotic induced liver injury: what about children?. <i>Journal of Chemotherapy</i> , 2013 , 25, 255-72	2.3	8
316	Medikamentö induzierte Leberschädigung. 2013 , 09, 195-208		
315	Non-fatal and fatal liver failure associated with valproic acid. 2013 , 46, 63-8		24
314	A proposed modification to HyG law and Edish criteria in oncology clinical trials using aggregated historical data. 2013 , 22, 571-8		8
313	Idiosyncratic adverse drug reactions: current concepts. 2013 , 65, 779-808		212
312	Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. 2013 , 22, 190-8		24
311	Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration® Mini-Sentinel Distributed Database. 2013 , 22, 861-72		45
310	Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. 2013 , 136, 97-106		88
309	Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. 2013 , 25, 825-9		90
308	Pre-Clinical Assessment of the Potential Intrinsic Hepatotoxicity of Candidate Drugs. 2013 ,		7
307	HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. <i>PLoS ONE</i> , 2013 , 8, e68111	3-7	66
306	Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. <i>World Journal of Hepatology</i> , 2014 , 6, 17-32	3-4	55
305	Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for <i>Pneumocystis jirovecii</i> pneumonia. <i>PLoS ONE</i> , 2014 , 9, e106141	3-7	23

304	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <i>Annals of Hepatology</i> , 2014 , 13, 231-239	3.1	25
303	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. 2014 , 13, 1305-17		7
302	Antidepressant-induced liver injury: a review for clinicians. 2014 , 171, 404-15		134
301	Hepatotoxicity induced by herbal and dietary supplements. 2014 , 34, 172-93		69
300	Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. 2014 , 34, 145-61		23
299	Hepatic toxicity biomarkers. 2014 , 241-259		12
298	Protective effect of linalool against lipopolysaccharide/D-galactosamine-induced liver injury in mice. 2014 , 23, 523-9		38
297	Incidence and outcomes of DILI in Western patients. <i>Clinical Liver Disease</i> , 2014 , 4, 9-11	2.2	5
296	Overview of drug-induced liver injury in China. <i>Clinical Liver Disease</i> , 2014 , 4, 26-29	2.2	12
295	Risk of oral antifungal agent-induced liver injury in Taiwanese. 2014 , 77, 180-9		42
294	Immune-Mediated Drug-Induced Liver Injury. 2014 , 401-412		3
293	Clinical features, diagnosis, and natural history of drug-induced liver injury. 2014 , 34, 134-44		48
292	Hepatic Adverse Drug Reactions. 2014 , 539-555		
291	Epidemiology and risk factors for idiosyncratic drug-induced liver injury. 2014 , 34, 115-22		57
290	DILI and drug development: a regulatory perspective. 2014 , 34, 215-26		20
289	Cholestasis in the Hospitalized Patient. <i>Clinical Gastroenterology</i> , 2014 , 201-228	0	
288	Drug-induced liver injury and drug development: industry perspective. 2014 , 34, 227-39		66
287	Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. 2014 , 147, 96-108.e4		142

286	Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy \odot Law. <i>Drug Safety</i> , 2014 , 37, 43-51	5.1	6
285	Drug-induced liver injury. 2014 , 89, 95-106		247
284	The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. 2014 , 42, 318-22		54
283	Use of Hy \odot law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. 2014 , 147, 109-118.e5		186
282	Idiosyncratic drug-induced liver injury: an update on the 2007 overview. 2014 , 13, 67-81		41
281	Correlation of antituberculosis drug-related liver injury and liver function monitoring: A 12-year experience of the Taiwan Drug Relief Foundation. 2014 , 22, 356-362		7
280	Cholestatic Liver Disease. <i>Clinical Gastroenterology</i> , 2014 ,	o	6
279	Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools. 2014 , 10, 581-97		26
278	Efficacy of Jian \odot anle () versus Huga \odot Pian (), glucuronolactone and reduced glutathione in prevention of antituberculosis drug-induced liver injury. 2014 , 34, 450-455		2
277	The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. 2014 , 18, 165-78		26
276	Drug-induced liver injury, dosage, and drug disposition: is idiosyncrasy really unpredictable?. 2014 , 12, 1556-61		5
275	Role of genetics in diagnosis and therapy of acquired liver disease. 2014 , 37, 15-34		5
274	Drug-induced liver injury: morbidity, mortality, and Hy \odot law. 2014 , 147, 20-4		26
273	Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes. 2014 , 28, 1136-43		9
272	[New perspectives and understanding in drug-induced liver injury considering drug metabolism and immune- and inflammation-related factors]. 2014 , 144, 22-7		1
271	Mining hidden knowledge for drug safety assessment: topic modeling of LiverTox as a case study. 2014 , 15 Suppl 17, S6		7
270	Hepatobiliary Quiz (Answers)-16 (2015). <i>Journal of Clinical and Experimental Hepatology</i> , 2015 , 5, 357-60 4.1		
269	[Establishment of animal models of drug-induced liver injury and analysis of possible mechanisms]. 2015 , 135, 579-88		7

268	High-Content Imaging in Human and Rat Hepatocytes Using the Fluorescent Dyes CLF and CMFDA Is Not Specific Enough to Assess BSEP/Bsep and/or MRP2/Mrp2 Inhibition by Cholestatic Drugs. 2015 , 1, 198-212	5
267	Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. 2015 , 24, 427-34	10
266	Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children. 2015 , 34, e153-8	9
265	Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature. 2015 , 1, 30-33	8
264	Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. 2015 , 3, 99-108	36
263	Carbamazepine-Induced Liver Injury Requires CYP3A-Mediated Metabolism and Glutathione Depletion in Rats. 2015 , 43, 958-68	26
262	Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. 2015 , 4, 802	23
261	Drug-induced liver injury: an overview over the most critical compounds. 2015 , 89, 327-34	86
260	The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond. 2015 , 13, 2173-89.e8	51
259	Investigations of the total flavonoids extracted from flowers of <i>Abelmoschus manihot</i> (L.) Medic against α -naphthylisothiocyanate-induced cholestatic liver injury in rats. 2015 , 172, 202-13	33
258	Drug-Induced Liver Injury. 2015 , 139, 876-87	100
257	Recent advances in management of acute liver failure. 2015 , 19, 27-33	20
256	Spectrum of Eosinophilic End-Organ Manifestations. 2015 , 35, 403-11	32
255	Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury. 2015 , 50, 439-46	14
254	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015 , 35, 2474-82	7.9 31
253	Characterization and treatment of persistent hepatocellular secretory failure. <i>Liver International</i> , 2015 , 35, 1478-88	7.9 19
252	Scandinavian epidemiological research in gastroenterology and hepatology. 2015 , 50, 636-48	4
251	Drug-induced cholestasis detection in cryopreserved rat hepatocytes in sandwich culture. 2015 , 73, 63-71	19

250	Update on acute liver failure. 2015 , 21, 134-41		35
249	Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. <i>Liver International</i> , 2015 , 35, 370-80	7.9	50
248	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. 2015 , 41, 116-25		69
247	A shift in paradigm towards human biology-based systems for cholestatic-liver diseases. 2015 , 593, 5043-55		14
246	Is Making a Prognosis for Patients With Drug-induced Liver Injury Putting the Cart Before the Horse?. 2015 , 13, 2369-71		4
245	Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests. 2015 , 70, 3100-6		9
244	Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. 2015 , 148, 1353-61.e3		67
243	Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice. 2015 , 35, 142-51		19
242	Assessment of jaundice in the hospitalized patient. 2015 , 19, 155-70		4
241	Liver Failure. 2016 , 181-198		
240	Hepatotoxicity by Drugs: The Most Common Implicated Agents. 2016 , 17, 224		128
239	Biomarkers in DILI: One More Step Forward. <i>Frontiers in Pharmacology</i> , 2016 , 7, 267	5.6	43
238	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016 , 7, 280	5.6	
237	Liver injury from nonsteroidal anti-inflammatory drugs in the United States. <i>Liver International</i> , 2016 , 36, 603-9	7.9	46
236	Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. <i>Hepatology</i> , 2016 , 63, 590-603	11.2	144
235	Drug-Induced Liver Injury. 2016 , 27, 430-440		17
234	Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. 2016 , 6, 35434		93
233	Drug-Induced Liver Injury. 2016 , 503-507		

232	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. 2016 , 65, 532-42	82
231	Hepatotoxicity of targeted therapy for cancer. 2016 , 12, 789-802	10
230	Activation of necroptosis in human and experimental cholestasis. 2016 , 7, e2390	76
229	Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-induced Acute Liver Injury. 2016 , 119, 3-9	8
228	Integrative "-Omics" Analysis in Primary Human Hepatocytes Unravels Persistent Mechanisms of Cyclosporine A-Induced Cholestasis. 2016 , 29, 2164-2174	14
227	Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. 2016 , 17, 618-627	16
226	Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?. 2016 , 151, 1046-1051	30
225	Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. 2016 , 68, 27-38	9
224	Adverse drug reactions and organ damage: The liver. <i>European Journal of Internal Medicine</i> , 2016 , 28, 9-16	3.9 52
223	Mellow Yellow: Diagnosis and Management of Multifactorial Postoperative Jaundice. 2016 , 61, 2226-2230	0
222	Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis. 2016 , 46, 277-91	9
221	Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters. 2017 , 101, 501-509	24
220	Drug-induced liver injury due to antibiotics. 2017 , 52, 617-623	41
219	Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations. 2017 , 45, 523-531	12
218	Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics. 2017 , 31, 2696-2708	90
217	Liver Transplantation for Acute Liver Failure. 2017 , 95, 181-189	2
216	Metabolic Activation of Cholestatic Drug-Induced Bile Acid-Dependent Toxicity in Human Sandwich-Cultured Hepatocytes. 2017 , 106, 2509-2514	6
215	CQMUH-011, a novel adamantane sulfonamide compound, inhibits lipopolysaccharide- and D-galactosamine-induced fulminant hepatic failure in mice. 2017 , 47, 231-243	6

214	Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM. <i>Drug Safety</i> , 2017 , 40, 715-727	5.1	10
213	Hepatotoxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors: clinical practice and evidence. 2017 , 33, 395-402		
212	Penicillinase-resistant antibiotics induce non-immune-mediated cholestasis through HSP27 activation associated with PKC/P38 and PI3K/AKT signaling pathways. 2017 , 7, 1815		23
211	Death and liver transplantation within 2 years of onset of drug-induced liver injury. <i>Hepatology</i> , 2017 , 66, 1275-1285	11.2	58
210	Approach to Severe Cutaneous Adverse Drug Reactions. 2017 , 4, 201-221		2
209	Role of Human Wharton® Jelly Derived Mesenchymal Stem Cells (WJ-MSCs) for Rescue of d-Galactosamine Induced Acute Liver Injury in Mice. <i>Journal of Clinical and Experimental Hepatology</i> , 2017 , 7, 205-214	4.1	6
208	Drug-induced liver injury: recent advances in diagnosis and risk assessment. 2017 , 66, 1154-1164		250
207	Drug-induced liver injury in Oncology. 2017 , 28, 2013-2020		21
206	Antiepileptic Drugs and Liver Disease. 2017 , 77, 23-36		37
205	Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?. 2017 , 16, 258-264		17
204	Liver transplantation for acute liver failure. 2017 , 95, 181-189		4
203	Validation of gene expression profiles from cholestatic hepatotoxicants in vitro against human in vivo cholestasis. 2017 , 44, 322-329		7
202	Autoimmune Hepatitis-Induced by Drugs: a Challenging Diagnosis. 2017 , 16, 265-270		1
201	MMP-2-Sensitive HA End-Conjugated Poly(amidoamine) Dendrimers via Click Reaction To Enhance Drug Penetration into Solid Tumor. 2017 , 9, 42459-42470		68
200	Drug-induced cholestasis. 2017 , 1, 726-735		59
199	Acute Liver Failure Induced by Anti-infectious Drugs: Causes and Management. 2017 , 16, 276-285		5
198	Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes. 2017 , 51, 63-69		42
197	The Causes and Clinical Spectrum of Drug-Induced Cholestatic Liver Injury. 2017 , 16, 130-136		

196	Hepatotoxicity of statins and other lipid-lowering agents. <i>Liver International</i> , 2017 , 37, 173-178	7.9	64
195	Drug-Induced Liver Disease: Clinical Course. 2017 , 21, 21-34		15
194	New Approaches to Investigate Drug-Induced Hypersensitivity. 2017 , 30, 239-259		15
193	Toxicological role of an acyl glucuronide metabolite in diclofenac-induced acute liver injury in mice. 2017 , 37, 545-553		22
192	Hepatotoxicity associated with statins. 2017 , 68, 254-260		19
191	Drug-induced Hepatotoxicity. 2017 , 740-773		3
190	A case of drug-induced liver injury with prolonged severe intrahepatic cholestasis induced by Ashwagandha. 2017 , 58, 448-454		6
189	Ciprofloxacin-induced Hepatotoxicity in a Healthy Young Adult. <i>Cureus</i> , 2017 , 9, e1016	1.2	6
188	Pathogenesis of Idiosyncratic Drug Induced Liver Injury. 2017 , 87-100		3
187	Drug-Induced Liver Injury: Mechanism-Informed Prediction in Drug Development. 2017 , 217-238		2
186	Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics. 2017 , 42, 427-436		10
185	Drug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality. <i>Annals of Hepatology</i> , 2017 , 16, 442-450	3.1	32
184	Mortality associated with drug-induced liver injury (DILI). 2017 , 2, 114		9
183	Noninvasive Imaging of Drug-Induced Liver Injury with F-DFA PET. 2018 , 59, 1308-1315		7
182	Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?. <i>Drug Safety</i> , 2018 , 41, 735-743	5.1	50
181	Evaluating Mitotoxicity as Either a Single or Multi-Mechanistic Insult in the Context of Hepatotoxicity. 2018 , 73-92		
180	An update on adverse drug reactions related to β -lactam antibiotics. 2018 , 17, 499-508		22
179	Nonacetaminophen Drug-Induced Acute Liver Failure. 2018 , 22, 301-324		3

178	Rapid bupropion-induced hepatotoxicity: a case report and review of the literature. 2018 , 12, 46	2
177	In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist. 2018 , 92, 1909-1912	12
176	Features and outcomes from a retrospective study of 570 hospitalized Chinese patients with drug-induced liver injury. 2018 , 42, 48-56	12
175	MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury. 2018 , 18, 47-54	41
174	In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials. 2018 , 243, 300-307	17
173	Biochemical Alterations in Acute Liver Failure and Its Relation with Prognosis. 2018 , 13, 17-19	
172	Human hepatocyte systems for in vitro toxicology analysis. 2018 , 3, 85-93	14
171	Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. 2018 , 625-650	
170	Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method. 2018 , 14, 1169-1187	24
169	Detection of Hepatotoxicity in Clinical and Experimental Settings. 2018 , 151-167	
168	Clinical Considerations of Drug-Induced Hepatotoxicity. 2018 , 608-624	
167	Piceatannol attenuates D-GalN/LPS-induced hepatotoxicity in mice: Involvement of ER stress, inflammation and oxidative stress. 2018 , 64, 131-139	27
166	Long-Term Outcomes After Drug-Induced Liver Injury. 2018 , 17, 292-299	14
165	Drug-induced liver injury: a safety review. 2018 , 17, 795-804	21
164	Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives. 2018 , 19, 830-838	53
163	Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems. 2018 , 120, 196-212	9
162	Drugs and Toxins. 2018 , 673-779	9
161	In vivo evaluation of hypolipidemic and antioxidative effect of <i>Ajwa</i> (Phoenix dactylifera L.) date seed-extract in high-fat diet-induced hyperlipidemic rat model. 2018 , 107, 675-680	24

160 Clinical Features of Liver Disease. **2018**, 33-42

159 Liver Injury Due to Drugs and Herbal Agents. **2018**, 327-370

0

158 Drug-Induced Liver Injury. **2018**, 468-493

3

157 Regional and Racial Differences in Drug-Induced Liver Injury. **2019**, 18, 280-286

156 Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver. *Biological and Pharmaceutical Bulletin*, **2019**, 42, 1366-1375

2.3 6

155 A rare case of cefepime-induced cholestatic liver injury. **2019**, 31, 124-128

6

154 Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. *Liver International*, **2019**, 39, 1906-1917

7.9 17

153 Global Epidemiology of Drug-Induced Liver Injury (DILI). **2019**, 18, 274-279

5

152 Herb induced liver injury after using herbal medicine: A systemic review and case-control study. **2019**, 98, e14992

18

151 Drug-induced liver injury. **2019**, 5, 58

148

150 Acute liver failure. **2019**, 394, 869-881

191

149 Idiosyncratic drug-induced liver injury in patients: Detection, severity assessment, and regulatory implications. **2019**, 85, 165-193

8

148 Experimental Cholestasis Research. **2019**,

2

147 Mechanisms of Drug-Induced Cholestasis. **2019**, 1981, 1-14

5

146 Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. **2019**, 156, 2230-2241.e11

185

145 Experimental Evidence of Liver Injury by BSEP-Inhibiting Drugs With a Bile Salt Supplementation in Rats. **2019**, 170, 95-108

4

144 Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. **2019**, 39, 381-394

14

143 Transcriptomic Analysis of Cholestatic Compounds In Vitro. **2019**, 1981, 175-186

2

142	Research Progress on the Animal Models of Drug-Induced Liver Injury: Current Status and Further Perspectives. 2019 , 2019, 1283824		15
141	EASL Clinical Practice Guidelines: Drug-induced liver injury. 2019 , 70, 1222-1261		327
140	Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. 2019 , 284, 66-74		31
139	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. 2019 , 49, 702-713		16
138	Drug-Induced Liver Disease: Mechanism and Diagnosis. 2019 , 715-728		1
137	Mechanisms of idiosyncratic drug-induced liver injury. 2019 , 85, 133-163		15
136	A prospective study of hepatic safety of statins used in very elderly patients. <i>BMC Geriatrics</i> , 2019 , 19, 352	4.1	5
135	Novel biomarkers for potential risk stratification of drug induced liver injury (DILI): A narrative perspective on current trends. 2019 , 98, e18322		9
134	Prednisone is not beneficial for the treatment of severe drug-induced liver injury: An observational study (STROBE compliant). 2019 , 98, e15886		6
133	Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. 2019 , 114, 929-937		25
132	Primary hepatocytes and their cultures for the testing of drug-induced liver injury. 2019 , 85, 1-30		10
131	A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. <i>Hepatology</i> , 2019 , 70, 621-629	11.2	15
130	Geraniol protects against lipopolysaccharide and D-galactosamine-induced fulminant hepatic failure by activating PPAR α . 2019 , 128, 7-12		4
129	Optimized protocol for induction of cytochrome P450 enzymes 1A2 and 3A4 in human primary-like hepatocyte cell strain HepaFH3 to study in vitro toxicology. 2018 , 70, 563-571		2
128	Serum biomarkers of drug-induced liver injury: Current status and future directions. 2019 , 20, 2-10		13
127	Statin Intolerance Clinical Guide 2018. 2020 , 27, 375-396		7
126	TianJiu therapy for α -naphthyl isothiocyanate-induced intrahepatic cholestasis in rats treated with fresh <i>Ranunculus sceleratus</i> L. 2020 , 248, 112310		3
125	Requirements for designing organ-on-a-chip platforms to model the pathogenesis of liver disease. 2020 , 181-213		2

124	Epidemiology, Predisposing Factors, and Outcomes of Drug-Induced Liver Injury. 2020 , 24, 1-10		14
123	High-Throughput Screening to Evaluate Inhibition of Bile Acid Transporters Using Human Hepatocytes Isolated From Chimeric Mice. 2020 , 173, 347-361		8
122	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. <i>Liver International</i> , 2020 , 40, 6-17	7.9	16
121	Drug-Induced Liver Injury from Statins. 2020 , 24, 107-119		8
120	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. 2020 , 19, 131-148		82
119	Liver safety assessment in clinical trials of new agents for chronic hepatitis B. 2020 , 27, 96-109		3
118	Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth. 2020 , 34, 72-86		32
117	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020 , 72, 671-722	11.2	198
116	Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. 2020 , 7,		25
115	An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management. 2020 , 48-49, 101691		2
114	A Severe Case of Drug-Induced Liver Injury after Gemcitabine Administration: A Highly Probable Causality Grading as Assessed by the Updated RUCAM Diagnostic Scoring System. 2020 , 2020, 8812983		1
113	[Acute liver failure-The importance of rapid diagnostics and early initiation of treatment]. 2020 , 61, 1151-1162		
112	An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids. <i>Drug Safety</i> , 2020 , 43, 1267-1276	5.1	8
111	Liver Failure. 2020 ,		1
110	Drug induced liver injury: an update. 2020 , 94, 3381-3407		40
109	Severe drug-induced liver injury in patients under treatment with antipsychotic drugs: Data from the AMSP study. 2021 , 22, 373-386		2
108	Cholestasis Differentially Affects Liver Connexins. 2020 , 21,		1
107	Drug-induced liver injury in older people. 2020 , 5, 862-874		20

106	Liver Injury Associated with the Selective Progesterone Modulator Ulipristal. <i>Drug Safety</i> , 2020 , 43, 12015-1204 2		
105	Presentations, Causes and Outcomes of Drug-Induced Liver Injury in Egypt. 2020 , 10, 5124		7
104	Cholangiolytic Changes in Statin-Induced Liver Injury. 2020 , 2020, 9650619		1
103	Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease. 2020 , 7, 8		7
102	Drug reactions with eosinophilia and systemic symptoms. 2020 , 20, 65-71		2
101	Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. 2020 , 30, 229-253		14
100	Drug induced liver injury is associated with high mortality-A study from a tertiary care hospital in Pakistan. <i>PLoS ONE</i> , 2020 , 15, e0231398	3-7	5
99	Antibiotics-induced oxidative stress. 2020 , 20-21, 23-28		0
98	The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients. <i>Journal of Clinical and Experimental Hepatology</i> , 2021 , 11, 288-298 4-1		10
97	Models of Idiosyncratic Drug-Induced Liver Injury. 2021 , 61, 247-268		8
96	Drug-Induced Cholangiopathies. 2021 , 211-227		
95	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. 2021 , 15, 258-282		15
94	A rare case of ciprofloxacin-induced cholestatic hepatitis in the newborn. 2021 , 001-003		
93	Outcomes and Predictors of Mortality in Patients With Drug-Induced Liver Injury at a Tertiary Hospital in South India: A Single-Centre Experience. <i>Journal of Clinical and Experimental Hepatology</i> , 2021 , 11, 163-170	4-1	2
92	Serious liver injury induced by Nimesulide: an international collaborative study. 2021 , 95, 1475-1487		3
91	Liver Injury Associated With Drugs and Complementary and Alternative Medicines in India. <i>Journal of Clinical and Experimental Hepatology</i> , 2021 ,	4-1	
90	Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. 2021 , 9, 730		4
89	NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity. 2021 , 9, 634607		5

88	Liver Injury Associated With Drugs and Complementary and Alternative Medicines in India. <i>Journal of Clinical and Experimental Hepatology</i> , 2021 , 11, 281-283	4.1	1
87	The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions. 2021 , 73, 861-896		3
86	Clinical management of patients with drug-induced liver injury (DILI). 2021 , 9, 781-786		2
85	Drug-induced liver injury at a tertiary care centre in Germany: Model for end-stage liver disease is the best predictor of outcome. <i>Liver International</i> , 2021 , 41, 2383-2395	7.9	0
84	Hepatic Bile Acid Transporters in Drug-Induced Cholestasis. 2021 , 307-337		
83	The Extended Clearance Model. 2021 , 455-479		
82	Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort. <i>PLoS Computational Biology</i> , 2021 , 17, e1009053	5	14
81	Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 3233-3238	4	1
80	Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. <i>Annals of Hepatology</i> , 2021 , 24, 100321	3.1	3
79	The LiverTox Paradox-Gaps between Promised Data and Reality Check. <i>Diagnostics</i> , 2021 , 11,	3.8	5
78	Signal Detection of Potential Hepatotoxic Drugs: Case-Control Study Using Both a Spontaneous Reporting System and Electronic Medical Records. <i>Biological and Pharmaceutical Bulletin</i> , 2021 , 44, 1514-1523	2.3	0
77	Drug-Induced Liver Injury. 2021 ,		
76	A monoterpene antioxidant, linalool, mitigates benzene-induced oxidative toxicities on hematology and liver of male rats. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2021 , 8, 39-53	1.3	2
75	Drug Induced Liver Disease: Mechanisms and Diagnosis. 2010 , 771-786		0
74	Primary Biliary Cirrhosis and Autoimmune Cholangitis. 2007 , 235-247		1
73	Liver Disease Caused by Drugs. 2010 , 1413-1446.e8		2
72	Nitrofurantoin immune-mediated drug-induced liver injury: a serious complication of a commonly prescribed medication. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	6
71	Autoimmune hepatitis unmasked by nimesulide. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	1

70	Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. <i>BMJ Open Gastroenterology</i> , 2020 , 7,	3.9	3
69	A Case of LevoBxacin-Induced Hepatotoxicity. <i>American Journal of Case Reports</i> , 2018 , 19, 272-276	1.3	3
68	Dyslipidemia is a Risk Factor for the Incidence and Severity of Drug-Induced Liver Injury (DILI): A Retrospective Population-Based Study in China. <i>Medical Science Monitor</i> , 2019 , 25, 3344-3353	3.2	7
67	Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. <i>World Journal of Clinical Cases</i> , 2019 , 7, 705-716	1.6	12
66	High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. <i>PLoS ONE</i> , 2016 , 11, e0151587	3.7	39
65	Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine. <i>BiolImpacts</i> , 2016 , 6, 3-8	3.5	29
64	Sulfasalazine-Induced Hepatic Injury in an Ex Vivo Model of Isolated Perfused Rat Liver and the Protective Role of Taurine. <i>Pharmaceutical Sciences</i> , 2015 , 21, 211-219		10
63	Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. <i>Drug Safety</i> , 2012 , 35, 1091-7	5.1	14
62	Epidemiology and Risk Factors for Severe Delayed Drug Hypersensitivity Reactions. <i>Current Pharmaceutical Design</i> , 2019 , 25, 3799-3812	3.3	4
61	Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5972-8	5.6	24
60	Atypical causes of cholestasis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9418-26	5.6	50
59	Drug-induced liver damage with cholestasis. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 61-74	0.4	3
58	Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients. <i>Advanced Biomedical Research</i> , 2014 , 3, 168	1.2	7
57	Evaluation of Drug-Induced Liver Injury Developed During Hospitalization Using Electronic Health Record (EHR)-Based Algorithm. <i>Allergy, Asthma and Immunology Research</i> , 2020 , 12, 430-442	5.3	7
56	Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. <i>World Journal of Hepatology</i> , 2014 , 6, 601-12	3.4	48
55	Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. <i>World Journal of Hepatology</i> , 2015 , 7, 1761-71	3.4	33
54	Drug-induced liver injury: Do we know everything?. <i>World Journal of Hepatology</i> , 2017 , 9, 491-502	3.4	47
53	Drug-Induced Liver Injury: Pattern Recognition and Future Directions. <i>Gut and Liver</i> , 2016 , 10, 27-36	4.8	34

52	Rosuvastatin Use Implicated in the Drug Reaction with Eosinophilia and Systemic Symptoms. <i>Cureus</i> , 2020 , 12, e7098	1.2	2
51	NSAID-induced liver damage with cholestasis. <i>Medical Alphabet</i> , 2021 , 37-48	0.3	
50	Drugs and liver injury: a not to be overlooked binomial in COVID-19. <i>Journal of Chemotherapy</i> , 2021 , 1-14.	3	1
49	15 Medicamenteus-toxisch leverlijden. 2009 , 149-159		
48	Drug-Induced Liver Injury in Children: A Structured Approach to Diagnosis and Management. 2014 , 371-388		
47	Drug-Induced Cholestasis. <i>Clinical Gastroenterology</i> , 2014 , 13-31	0	1
46	Adverse Drug Reactions in the ICU. 2016 , 1-47		
45	Liver transplantation in patients with fulminant hepatitis. 2017 , 1766-1780.e4		
44	Drug-Related Acute Hepatitis. 2017 , 146-149		
43	Adverse Drug Reactions in the Intensive Care Unit. 2017 , 693-739		1
42	Syndrome of intrahepatic cholestasis in patients with acute and chronic intoxication with pesticides. <i>Ukrainian Journal of Modern Toxicological Aspects</i> , 2018 , 81, 39-48	0.2	1
41	THE MORPHOLOGICAL STRUCTURE OF THE LIVER AND ITS FUNCTIONAL STATE AT MEDICINAL DAMAGE AND TREATMENT BY THE NEW PHARMACEUTICAL COMPOSITION. <i>Morphological Newsletter</i> , 2018 , 26, 12-16	0.2	
40	Immune-Mediated Drug-Induced Liver Injury. 2020 , 491-504		
39	Etiological evaluation of the elevated transaminases in children. <i>Cumhuriyet Medical Journal</i> ,	0	
38	Risk of antimicrobial-associated organ injury among the older adults: a systematic review and meta-analysis. <i>BMC Geriatrics</i> , 2021 , 21, 617	4.1	0
37	Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM. <i>Frontiers in Pharmacology</i> , 2021 , 12, 761167	5.6	4
36	Drug-Induced Acute and Acute on Chronic Liver Failure. 2020 , 219-232		
35	Medikamentö-toxischer Leberschaden (DILI). <i>Pathologie</i> , 2020 , 117-157	0	

34	Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations. <i>Drug Safety</i> , 2012 , 35, 865-875	5.1	1
33	Drug-induced liver injuries in practice of primary care physician (review of clinical recommendations). <i>Medical Alphabet</i> , 2020 , 58-69	0.3	1
32	Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. <i>Indian Journal of Medical Research</i> , 2013 , 138, 461-91	2.9	13
31	Puzzling postoperative toxin-induced acute liver failure after nonhepatobiliary surgery. <i>Saudi Journal of Anaesthesia</i> , 2018 , 12, 658-659	1.2	1
30	Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. <i>European Journal of Internal Medicine</i> , 2021 ,	3.9	2
29	Liver Injury Following <i>Tinospora Cordifolia</i> Consumption: Drug-Induced AIH, or AIH?. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 , 12, 6-9	4.1	1
28	Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 806249	5.6	5
27	Drug-Induced Liver Injury: A Mexican View.. <i>Clinical Liver Disease</i> , 2022 , 19, 78-81	2.2	
26	HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure.. <i>Pharmacogenomics Journal</i> , 2022 ,	3.5	1
25	Association Between Drug Treatments and the Incidence of Liver Injury in Hospitalized Patients With COVID-19.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 799338	5.6	0
24	Activated Carbon/Pectin Composite Enterosorbent for Human Protection from Intoxication with Xenobiotics Pb(II) and Sodium Diclofenac.. <i>Molecules</i> , 2022 , 27,	4.8	1
23	Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review. <i>Pharmaceutics</i> , 2022 , 14, 1190	6.4	0
22	Drug-Induced Liver Injury. 2022 , 237-263		
21	An Unusual Case of Drug-Induced Liver Injury Secondary to Nitrofurantoin Use. <i>Cureus</i> , 2022 ,	1.2	
20	Detection of Synergistic Interaction on an Additive Scale Between Two Drugs on Abnormal Elevation of Serum Alanine Aminotransferase Using Machine-Learning Algorithms. <i>Frontiers in Pharmacology</i> , 13,	5.6	
19	Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 13,	5.6	
18	A new framework for advancing in Drug-Induced Liver Injury research. The Prospective European DILI Registry. <i>Liver International</i> ,	7.9	1
17	AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.		1

16 Oncological-Therapy-Associated Liver Injuries.

15 Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis. 9, 1

14 Predicting adverse drug events in older inpatients: a machine learning study. 0

13 Predicting hepatotoxicity associated with low-dose methotrexate using machine learning. 0

12 Enlarging the Stokes Shift by Weakening the π -Conjugation of Cyanines for High Signal-to-Noise Ratiometric Imaging. 2205080 0

11 Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. 0

10 7, 8-Dihydroxy-4-methyl coumarin alleviates cholestasis via activation of the Farnesoid X receptor in vitro and in vivo. **2022**, 110331 0

9 Molecular and Antioxidant Characterization of Opuntia robusta Fruit Extract and Its Protective Effect against Diclofenac-Induced Acute Liver Injury in an In Vivo Rat Model. **2023**, 12, 113 0

8 Drug-induced liver injury: An overview and update. **2023**, 0

7 The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors. 13, 1

6 Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations. **2023**, 24, 6663 0

5 Predicting Hepatotoxicity Associated with Low-Dose Methotrexate Using Machine Learning. **2023**, 12, 1599 0

4 Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies. **2023**, 15, 0

3 Drug-Induced Liver Injury in Tuberculosis: Mechanisms of Development and Diagnostic Methods. **2023**, 9, 24-42 0

2 A Novel Drug with Potential to Treat Hyperbilirubinemia and Prevent Liver Damage Induced by Hyperbilirubinemia: Carbon Dots Derived from Platycodon grandiflorum. **2023**, 28, 2720 0

1 Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins. **2024**, 726-841 0